Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04097145 · ClinicalTrials.gov registry record · NA

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

A NA study of Tricuspid Regurgitation and Tricuspid Valve Disease, sponsored by Edwards Lifesciences.

Recruiting
Registry status
NA
Development phase
870
Enrollment target
20
Study locations

NCT04097145 is a NA study of Tricuspid Regurgitation and Tricuspid Valve Disease that is actively recruiting participants, run by Edwards Lifesciences. The registered enrollment target is 870 participants, above the 485-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (79% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04097145, a NA study of Tricuspid Regurgitation and Tricuspid Valve Disease, is actively recruiting participants, sponsored by Edwards Lifesciences.

RECRUITING
Registry status
NA
Development phase
870 participants
Enrollment target
20
Study locations

Study Summary

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

Interventions

  • DEVICE Edwards PASCAL System
  • DRUG Optimal Medical Therapy

Study Locations (20)

California

  • University of California, Irvine - Irvine
  • SCPMG - Kaiser San Diego - La Jolla
  • Cedars Sinai Medical Center - Los Angeles
  • UCLA Medical Center - Los Angeles
  • Kaiser Permanente San Francisco - San Francisco
  • University of California, San Francisco - San Francisco
  • Stanford University - Stanford

Florida

  • The Cardiac and Vascular Institute Research Foundation - Gainesville
  • Mount Sinai Medical Center - Miami Beach
  • NCH Healthcare System - Naples
  • Sarasota Memorial Health Care System - Sarasota
  • Tallahassee Research Institute - Tallahassee

Arizona

  • Banner University Medical Center Phoenix - Phoenix
  • Tucson Medical Center Healthcare - Tucson

Colorado

  • St. Joseph Hospital - Denver
  • Medical Center of the Rockies - Loveland

Georgia

  • Emory University Hospital Midtown / Emory University - St. Joseph's Hospital - Atlanta
  • Piedmont Healthcare, Inc. - Atlanta

Illinois

  • Northwestern University - Chicago

Indiana

  • Ascension St. Vincent Heart Center Cardiovascular Research Institute - Indianapolis

Trial Details

FieldValue
Enrollment Target 870 participants
Start Date 2019-12-11
Est. Completion 2031-12-31
Phase NA

Sponsor

Edwards Lifesciences

57 total trials

What the Registry Record Tells You About NCT04097145

The ClinicalTrials.gov registry entry for NCT04097145 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 870 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 485-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (79% higher). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 2 interventions - of which Edwards PASCAL System is the first listed.

NCT04097145 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT04097145 about?

NCT04097145 is a clinical study titled "Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial". To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with co...

What is the current status of trial NCT04097145?

This trial is currently recruiting. It is a NA study. The enrollment target is 870 participants. The study started on 2019-12-11. Estimated completion is 2031-12-31.

What conditions does trial NCT04097145 study?

This clinical trial studies the following conditions: Tricuspid Regurgitation, Tricuspid Valve Disease, Tricuspid Valve Insufficiency.

What interventions are being tested in trial NCT04097145?

The interventions under investigation include: Edwards PASCAL System (DEVICE), Optimal Medical Therapy (DRUG).

Who is sponsoring clinical trial NCT04097145?

This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04097145 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tricuspid Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.